The EMA implements stringent pharmacovigilance measures to monitor the safety of gynecological medicines post-approval. This includes adverse event reporting systems, periodic safety update reports (PSURs), and risk management plans (RMPs). These measures help identify and mitigate any potential risks associated with gynecological drugs.
